(88 days)
Not Found
No
The summary describes a standard blood glucose monitoring system using an amperometric detection method. There is no mention of AI or ML in the intended use, device description, or performance studies. The presence of a 4G module is for data transmission, not AI/ML processing.
No
Explanation: A therapeutic device is used to treat or cure a disease. This device is an in vitro diagnostic device used to measure glucose levels, which aids in monitoring the effectiveness of diabetes control, but it does not directly treat or cure diabetes.
No.
Explanation: The device is intended for monitoring diabetes effectiveness and explicitly states, "It is not intended for neonatal use or for the diagnosis of or screening for diabetes." This indicates it is not a diagnostic device.
No
The device description explicitly states that the system is comprised of a blood glucose meter and test strips, and describes the physical and chemical processes involved in the measurement, indicating hardware components are essential to its function.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states:
"This system is intended for self-testing outside the body (in vitro diagnostic use)..."
This statement clearly identifies the device as being intended for in vitro diagnostic use.
N/A
Intended Use / Indications for Use
VivaChek™ Link Plus Blood Glucose Monitoring System is comprised of the VivaChek™ Link Plus Blood Glucose Meter and the VivaChek™ Ino Blood Glucose Test Strips.
VivaChek™ Link Plus Blood Glucose Monitoring System is intended to quantitatively measure the glucose concentration in fresh capillary whole blood samples drawn from the fingertips. It is intended for use by persons with diabetes at home as an aid to monitor the effectiveness of diabetes control. It is not intended for neonatal use or for the diagnosis of or screening for diabetes. This system is intended for self-testing outside the body (in vitro diagnostic use), and should only be used by a single person and should not be shared.
Product codes (comma separated list FDA assigned to the subject device)
NBW
Device Description
VivaChek Link Plus Blood Glucose Monitoring System is designed to quantitatively measure the glucose concentration in fresh capillary whole blood. The glucose measurement is achieved by using the amperometric detection method. The test is based on measurement of electrical current caused by the reaction of the glucose with the reagents on the electrode of the test strip. The blood sample is pulled into the tip of the test strip through capillary action. Glucose in the sample reacts with glucose oxidase and the mediator. Electrons are generated, producing a current that is positive correlation to the glucose concentration in the sample. After the reaction time, the glucose concentration in the sample is displayed.
VivaChek Link Plus Blood Glucose Monitoring System contains 4G module, the device complies with US federal guidelines, FCC Part 15 Subpart B, FCC Part 2, FCC Part 24 Subpart E, FCC Part 27 Subpart C, and FCC 47 CFR§ 2.1093 based on the test reports.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
fingertips
Indicated Patient Age Range
Not intended for neonatal use.
Intended User / Care Setting
persons with diabetes at home, self-testing, single person use, not to be shared.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The performance characteristics of the VivaChek Link Plus Blood Glucose Monitoring System were evaluated by performing the following studies:
- Within-Run Precision Evaluation
- Intermediate Precision Evaluation
- Linearity Evaluation Study
- User Evaluation
- User Evaluation - Accuracy at Extreme Glucose Values
- Usability Evaluation
- Interference Agents Study
- Accelerated Closed Vial Stability Study
- Accelerated Open Vial Stability Study
- System Operating Conditions Evaluation
- Altitude Effect Evaluation
- Error Messages Validation
- Short Sample Detection Study
- Sample Perturbation Study
- Intermittent Sampling Study
- Testing with Used Test Strips
- Test Strip Early Removal Validation
- Incorrect Strip Insertion Validation
- Shipping and Handling Study
- Oxygen Interference Study
- Hematocrit Effect Study
- Meter Environmental Temperature Test
- Vibration Testing
- Shock Testing
- Low Battery Study
- Recharging Temperature Limit Validation
- Cleaning and Disinfection Study
- Meter Robustness Study
- EMC Testing including the wireless connection testing
- Electrical Safety Testing
- FCC Testing
- Meter Software (Firmware) Validation
- Cybersecurity Control DFMEA
- Cybersecurity Management Plan
Key results:
"Above laboratory studies were performed on VivaChek Link Plus Blood Glucose Monitoring System in accordance with the applicable guidance or standards, and the test results indicated that the acceptance criteria were met. Therefore, the performances from these laboratory studies were acceptable."
"Clinical study (user evaluation) was conducted with intended users using the VivaChek Link Plus Blood Glucose Monitoring System. Study results indicated that non-professional, inexperienced lay persons were able to obtain blood glucose readings when using the VivaChek Link Plus Blood Glucose Monitoring System. In addition, the participated lay persons were questioned and responded as satisfied with the ease of operation by following the User Manual and the overall performance of the VivaChek Link Plus Blood Glucose Monitoring System."
"The laboratory studies and user evaluation study results demonstrate that the VivaChek Link Plus Blood Glucose Monitoring System is safe, effective and easy-to-use. It also demonstrates that the VivaChek Link Plus Blood Glucose Monitoring System meets FDA Guidance SMBG for OTC Use."
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
VivaChek Ino Smart Blood Glucose Monitoring System (K173140)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
December 22, 2023
VivaChek Biotech (Hangzhou) Co., Ltd. Mark Qian Quality Director Level 2, Block 2, 146 East Chaofeng Rd. Yuhang Economy Development Zone Hangzhou, Zhejiang 311100 China
Re: K233058
Trade/Device Name: VivaChek™ Link Plus Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW Dated: September 20, 2023 Received: September 25, 2023
Dear Mark Oian:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
2
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Yiduo Wu -S
for Joshua M. Balsam, Ph.D. Branch Chief Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K233058
Device Name
VivaChek™ Link Plus Blood Glucose Monitoring System
Indications for Use (Describe)
VivaChek™ Link Plus Blood Glucose Monitoring System is comprised of the VivaChek™ Link Plus Blood Glucose Meter and the VivaChek™ Ino Blood Glucose Test Strips.
VivaChek™ Link Plus Blood Glucose Monitoring System is intended to quantitatively measure the glucose concentration in fresh capillary whole blood samples drawn from the fingertips. It is intended for use by persons with diabetes at home as an aid to monitor the effectiveness of diabetes control. It is not intended for neonatal use or for the diagnosis of or screening for diabetes. This system is intended for self-testing outside the body (in vitro diagnostic use), and should only be used by a single person and should not be shared.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
| Prescription Use (Part 21 CFR 801 Subpart D)
|X | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Section F
Section F: 510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.
The Assigned 510(k) number is K233058.
Submitter's Identification:
VivaChek Biotech (Hangzhou) Co., Ltd Level 2, Block 2, 146 East Chaofeng Rd., Yuhang Economy Development Zone, Hangzhou, 311100, Zhejiang, China.
Date Updated: Dec 19, 2023
Contact Person:
Name: Mark Qian Position: Quality Director Email: mark.qian@vivachekbio.com
Proprietary Name of the Device:
VivaChek Link Plus Blood Glucose Monitoring System
Common Name: Glucose Test System
Classification Name:
Class II §862.1345 Glucose Test System Product Code: NBW
Predicate Device:
VivaChek Ino Smart Blood Glucose Monitoring System VivaChek Laboratories, Inc. 510(k) Number: K173140
4
Applicant: VivaChek Biotech (Hangzhou) Co., Ltd Address: Level 2, Block 2, 146 East Chaofeng Rd., Yuhang Economy Development Zone, Hangzhou, 311100, Zhejiang, China Contact: Mark Qian Email: mark.qian@vivachekbio.com
Section F
| Device Name: | ||||||
|---|---|---|---|---|---|---|
| Proprietary Name | Meter | |||||
| Model | Test Strips | |||||
| Model | Classification | Product | ||||
| Code | Description | Common | ||||
| Name | ||||||
| VivaChek Link Plus | ||||||
| Blood Glucose | ||||||
| Monitoring System | VGM90 | VGS01 | 862.1345 | |||
| Class II | NBW | System, Test, | ||||
| Blood Glucose, | ||||||
| Over The Counter | Glucose | |||||
| Test System |
Intended Use:
VivaChek Link Plus Blood Glucose Monitoring System is comprised of the VivaChek Link Plus Blood Glucose Meter and the VivaChek Ino Blood Glucose Test Strips. VivaChek Link Plus Blood Glucose Monitoring System is intended to quantitatively measure the glucose concentration in fresh capillary whole blood samples drawn from the fingertips. It is intended for use by persons with diabetes at home as an aid to monitor the effectiveness of diabetes control. It is not intended for neonatal use or for the diagnosis of or screening for diabetes. This system is intended for self-testing outside the body (in vitro diagnostic use), and should only be used by a single person and should not be shared.
Description:
VivaChek Link Plus Blood Glucose Monitoring System is designed to quantitatively measure the glucose concentration in fresh capillary whole blood. The glucose measurement is achieved by using the amperometric detection method. The test is based on measurement of electrical current caused by the reaction of the glucose with the reagents on the electrode of the test strip. The blood sample is pulled into the tip of the test strip through capillary action. Glucose in the sample reacts with glucose oxidase and the mediator. Electrons are generated, producing a current that is positive correlation to the glucose concentration in the sample. After the reaction time, the glucose concentration in the sample is displayed.
VivaChek Link Plus Blood Glucose Monitoring System contains 4G module, the device complies with US federal guidelines, FCC Part 15 Subpart B, FCC Part 2, FCC Part 24 Subpart E, FCC Part 27 Subpart C, and FCC 47 CFR§ 2.1093 based on the test reports.
5
Section F
Comparison to Predicate Device:
The VivaChek Link Plus Blood Glucose Monitoring System is substantially equivalent to VivaChek Ino Smart Blood Glucose Monitoring System (K173140).
| Features | Predicate: VivaChek Ino Smart Blood
Glucose Monitoring System (K173140) | Candidate: VivaChek Link
Plus Blood Glucose
Monitoring System |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Similarities | | |
| Intended Use | It is intended to quantitatively measure
the glucose concentration in fresh
capillary whole blood samples drawn
from the fingertips. It is intended for use
by persons with diabetes at home as an
aid to monitor the effectiveness of
diabetes control. It is not intended for
neonatal use or for the diagnosis of or
screening for diabetes. It is intended for
self-testing outside the body (in vitro
diagnostic use), and should only be
used by a single person and should not
be shared. | Same |
| Operation Principle | Electrochemical biosensor | Same |
| Detection Method | Amperometric | Same |
| Strip Chemical
Composition | Glucose oxidase | Same |
| Measurement Result | Plasma equivalent | Same |
| Sample | Fresh capillary whole blood | Same |
| Memory | 500 records | Same |
| Unit of Measure | mg/dL | Same |
| Measurement Range | 20-600 mg/dL | Same |
| Sample Volume | 0.8µL | Same |
| Test Time | 5 seconds | Same |
| Operating Relative
Humidity | 10-90% (non-condensing) | Same |
| Operating Temperature | 41-113°F | Same |
| Hematocrit Range | 20-70% | Same |
| Automatic Shutoff | 2 minutes after last action | Same |
| Power Source | Rechargeable 3.7 Volt Lithium Ion
battery | Same |
| Differences | | |
| Battery Type | Rechargeable, non-serviceable,
250mAh, 3.7 Volt DC nominal, lithium | Rechargeable, 800 mAh, 3.7
Volt DC nominal, lithium
polymer battery (5V input) |
| | polymer battery (5V input charge
voltage) | charge voltage) |
| Data Transmission | Bluetooth | 4G |
| Dimensions | 83 mm x 52 mm x 18.7 mm | 100.9mm x 61.6mm x 23.7mm |
| Display Size | 32mm x 32 mm | 42 mm x 41 mm |
| Weight | Approximately 53g | Approximately 85g |
6
Applicant: VivaChek Biotech (Hangzhou) Co., Ltd
Address: Level 2, Block 2, 146 East Chaofeng Rd., Yuhang Economy Development Zone, Hangzhou, 311100, Zhejiang, China Contact: Mark Qian Email: mark.qian@vivachekbio.com
Section F
Laboratory and Clinical Testing:
The performance characteristics of the VivaChek Link Plus Blood Glucose Monitoring System were evaluated by performing the following studies:
| No. | Test/Validation Item |
|---|---|
| 1 | Within-Run Precision Evaluation |
| 2 | Intermediate Precision Evaluation |
| 3 | Linearity Evaluation Study |
| 4 | User Evaluation |
| 5 | User Evaluation - Accuracy at Extreme Glucose Values |
| 6 | Usability Evaluation |
| 7 | Interference Agents Study |
| 8 | Accelerated Closed Vial Stability Study |
| 9 | Accelerated Open Vial Stability Study |
| 10 | System Operating Conditions Evaluation |
| 11 | Altitude Effect Evaluation |
| 12 | Error Messages Validation |
| 13 | Short Sample Detection Study |
| 14 | Sample Perturbation Study |
| 15 | Intermittent Sampling Study |
| 16 | Testing with Used Test Strips |
| 17 | Test Strip Early Removal Validation |
| 18 | Incorrect Strip Insertion Validation |
7
Applicant: VivaChek Biotech (Hangzhou) Co., Ltd
Address: Level 2, Block 2, 146 East Chaofeng Rd.,
Yuhang Economy Development Zone, Hangzhou, 311100, Zhejiang, China
Contact: Mark Qian Email: mark.qian@vivachekbio.com
Section F
| 19 | Shipping and Handling Study |
|---|---|
| 20 | Oxygen Interference Study |
| 21 | Hematocrit Effect Study |
| 22 | Meter Environmental Temperature Test |
| 23 | Vibration Testing |
| 24 | Shock Testing |
| 25 | Low Battery Study |
| 26 | Recharging Temperature Limit Validation |
| 27 | Cleaning and Disinfection Study |
| 28 | Meter Robustness Study |
| 29 | EMC Testing including the wireless connection testing |
| 30 | Electrical Safety Testing |
| 31 | FCC Testing |
| 32 | Meter Software (Firmware) Validation |
| 33 | Cybersecurity Control DFMEA |
| 34 | Cybersecurity Management Plan |
To confirm the 4G module has not brought any unexpected functional failure or adverse effect, FCC, cybersecurity control DFMEA, Cybersecurity Management Plan and Web App software validation were conducted.
Discussion of Laboratory Studies:
Above laboratory studies were performed on VivaChek Link Plus Blood Glucose Monitoring System in accordance with the applicable guidance or standards, and the test results indicated that the acceptance criteria were met. Therefore, the performances from these laboratory studies were acceptable.
8
Section F
Discussion of Clinical Study:
Clinical study (user evaluation) was conducted with intended users using the VivaChek Link Plus Blood Glucose Monitoring System. Study results indicated that non-professional, inexperienced lay persons were able to obtain blood glucose readings when using the VivaChek Link Plus Blood Glucose Monitoring System. In addition, the participated lay persons were questioned and responded as satisfied with the ease of operation by following the User Manual and the overall performance of the VivaChek Link Plus Blood Glucose Monitoring System.
Conclusion:
The laboratory studies and user evaluation study results demonstrate that the VivaChek Link Plus Blood Glucose Monitoring System is safe, effective and easy-to-use. It also demonstrates that the VivaChek Link Plus Blood Glucose Monitoring System meets FDA Guidance SMBG for OTC Use.
Based on the same intended use and work principle, and the same technological characteristics listed in the section Comparison to Predicate Device - Similarities, meanwhile the different technological characteristics listed in the section Comparison to Predicate Device do not raise safety and effectiveness questions according to the completed performance testing and validation reports, therefore the candidate device VivaChek Link Plus Blood Glucose Monitoring System is substantially equivalent to the predicate device VivaChek Ino Smart Blood Glucose Monitoring System (K173140).